F18.97
Inhalant use, unspecified with inhalant-induced persisting dementia
Clinical Classification Guidelines
Inclusion Terms
- Inhalant-induced major neurocognitive disorder
Medical Intelligence & Overview
Inhalant use refers to the recreational or compulsive inhalation of volatile substances to achieve a psychoactive effect. When these substances are used repeatedly over time, they can lead to significant cognitive decline, known as inhalant-induced persisting dementia, classified under ICD-10 code F18.97. This condition is a type of neurocognitive disorder where mental functions such as memory, thinking, and reasoning are affected due to inhalant abuse. Recognizing the causes, symptoms, and treatment options is crucial for those affected and their loved ones.
Causes & Symptoms
Clinical Causes: Repeated inhalation of volatile substances, such as solvents, aerosols, gases, or nitrites. Prolonged or excessive use of inhalants leading to toxic effects on brain tissue. Pre-existing mental health conditions and substance use disorders that may increase the likelihood of inhalant abuse. Environmental factors, like peer pressure or availability of inhalants, contributing to initiation and continued use.
Key Symptoms: Memory loss and difficulty concentrating. Impacts on judgment, decision-making, and problem-solving skills. Changes in behavior, including irritability, agitation, or paranoia. Reduced coordination and motor skills. Language difficulties and slurred speech. Decline in personal hygiene and self-care routine. Emotional disturbances such as depression or anxiety. In severe cases, hallucinations or delusional thinking.
Diagnostic & Treatment
Diagnosis Path: Diagnosis generally involves a comprehensive clinical assessment that includes reviewing the individual's history of inhalant use, mental status examinations, and neurocognitive testing. Brain imaging scans, such as MRI or CT scans, may reveal structural brain changes associated with prolonged inhalant toxicity. Healthcare providers may also perform laboratory tests to rule out other causes of cognitive impairment and confirm exposure to specific inhalants.
Treatment Protocols: Managing inhalant-induced dementia involves a multidisciplinary approach, focusing on both cessation of inhalant use and supportive therapy. Treatment options may include:
Clinical Advice & FAQs
Billing Guidance
Is F18.97 a billable ICD-10 code?
Yes, F18.97 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report F18.97?
Clinical documentation must specify the nature of Inhalant use, unspecified with inhalant-induced persisting dementia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference